Improving ILD Screening in Patients With RA and SSc Using EHR-Embedded CDS and PRO Tools (ILD-QUI)
This is a quality improvement initiative that aims to find better ways to identify interstitial lung disease (ILD) early in people with rheumatoid arthritis (RA) or systemic sclerosis (SSc). ILD is a serious lung problem that can develop in these conditions but is often missed. The project will test whether tools built into the electronic health record (EHR), including symptom surveys that patients complete on a tablet and alerts that help doctors decide when lung testing is needed, can increase screening rates.
About 16 rheumatology clinics that use the same EHR system will take part. All clinics will eventually use the new tools, but they will start at different times. This allows researchers to compare usual care to the new approach within each clinic.
Adults with RA or SSc who have not previously been diagnosed with ILD and who have not had recent lung testing will be included automatically through their routine clinic visits. The study expects to include about 800 patients in total.
The main question is whether more eligible patients receive recommended ILD screening, which includes either a pulmonary function test or a high-resolution CT scan, within seven days of their clinic visit. The study will also look at how often lung tests are ordered and completed, how often patients report symptoms such as shortness of breath or cough, and whether the alerts lead to real-time clinical decisions.
This project lasts two years and uses information already collected during routine clinical care. No additional procedures or medications are required.
調査の概要
詳細な説明
Interstitial lung disease (ILD) is a common and serious complication of rheumatoid arthritis (RA) and systemic sclerosis (SSc). Despite guideline recommendations, ILD screening in routine care remains low, and many patients are not evaluated until their lung disease is advanced. This study evaluates a pragmatic, clinic-integrated strategy designed to increase timely ILD screening using tools embedded directly into the electronic health record (EHR).
The project is conducted within community rheumatology practices that share a common EHR platform (NextGen). All participating sites transition from usual care to the intervention, but at different scheduled time points. This stepped-wedge design allows each site to contribute both control-phase and intervention-phase data. Screening is not researcher-initiated; instead, the intervention is designed to support and standardize existing clinical workflows.
The intervention consists of two components implemented at the clinic level. First, patients complete a brief respiratory symptom survey on a tablet at check-in. The questionnaire captures dyspnea and cough severity and is designed to take under two minutes. The results become available to clinicians in real time. Second, EHR-embedded clinical decision support (CDS) prompts appear for clinicians when patients meet predefined criteria based on diagnosis, test history, and symptom scores. These prompts remind clinicians of guideline-recommended ILD screening and facilitate ordering of pulmonary function tests or high-resolution computed tomography when appropriate. Sites also receive training and a structured workflow guide to support implementation.
Because the intervention is deployed within routine clinical care, patients are passively included when they present for appointments and meet study criteria in the EHR. No additional study visits, procedures, or medications are required. Data are collected from the EHR, CDS activity logs, and patient-reported surveys. The study observes ordering and completion of ILD screening tests, provider responses to alerts, symptom patterns, and documentation of new ILD diagnoses. Data are analyzed to compare screening activity before and after the clinic transitions to the intervention, adjusting for time effects and patient and site characteristics.
The study aims to generate practical evidence on whether embedding guideline-aligned CDS and rapid symptom assessments into existing workflows can improve ILD screening for RA and SSc patients in real-world community practice. Findings may help inform broader implementation strategies for early detection of ILD and other pulmonary complications in rheumatology populations.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jeffrey R Curtis, MD, MS, MPH
- 電話番号:205-937-0585
- メール:jc@fastermedicine.org
研究連絡先のバックアップ
- 名前:Stephanie S Ford, MS
- 電話番号:205-410-8480
- メール:sf@fastermedicine.org
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Participants must meet all of the following to be included:
Age ≥ 18 years Diagnosis of rheumatoid arthritis (RA) or systemic sclerosis (SSc) No prior diagnosis of interstitial lung disease (ILD) No high-resolution CT (HRCT) or pulmonary function test (PFT) within the past 24 months
Participants meeting any of the following are excluded:
Confirmed diagnosis of ILD Recent HRCT or PFT within the last 24 months without new symptoms
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:なし
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:EHR-Embedded CDS and PRO Tools
This is a quality-improvement, workflow-embedded intervention, the stepped-wedge design evaluates the effect of an active intervention (EHR-embedded CDS + PRO tools). |
This intervention integrates two components directly into routine rheumatology clinic workflows using the shared NextGen electronic health record (EHR). First, patients complete a brief tablet-based respiratory symptom questionnaire at check-in, capturing dyspnea and cough severity in under two minutes. Responses are transmitted instantly into the EHR. Second, the system activates ILD-focused clinical decision support (CDS) prompts for clinicians based on diagnosis, prior testing history, and symptom scores. These prompts recommend guideline-aligned ILD screening and provide structured options for ordering pulmonary function tests or high-resolution chest CT. The CDS also records provider responses and reasons for deferring screening. The intervention is deployed at the site level and is intended to standardize ILD screening behavior, enhance recognition of respiratory symptoms, and support timely clinical action in RA and SSc patients. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Receipt of ILD Screening
時間枠:Within 7 days of the index rheumatology clinic visit
|
Proportion of eligible patients who receive an ILD screening test (high-resolution CT [HRCT] or pulmonary function test [PFT]) within 7 days of a clinic visit. |
Within 7 days of the index rheumatology clinic visit
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- QIE 2024-10245
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IDP will not be shared because this study is a quality-improvement, workflow-embedded project that uses routine clinical data obtained through participating practices' EHR systems. Data use is restricted under site agreements, HIPAA requirements, and the terms of the QIE grant, which allow only aggregated, de-identified reporting and do not permit external sharing of IPD.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。